Funding
← Back to your selection

Samsara BioCapital

Activity from announced rounds

Activity in this selectionSeries B
Rounds participated in
3
Confirmed lead rounds
0
2 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$344M
3 disclosed · full round size, not this investor’s share

By stage

Series B3

By primary sector

Biotech3

By country

United States3

Rounds

3 in this selection
Ambrosia Biosciences

Drug-discovery company developing oral small-molecule treatments for obesity and metabolic disorders.

$100MSeries B
Participant
EpiBiologics

Develops bispecific antibodies for targeted degradation of extracellular proteins.

$107MSeries B
Role not disclosed